Jay Yadav

As one of Mammoth’s venture capital investment decision makers, Dr. Yadav has a long history of innovation which has improved the treatment of major public health problems such as heart failure and stroke. Companies under Jay’s leadership have created over $1 billion in shareholder value.

Jay Yadav is the Founder of CardioMEMS, randomized trial published in Lancet and Nature; acquired by (St. Jude Medical) Abbott. Dr. Yadav founded Angioguard, Inc., novel treatment for stroke which is now a Class 1 recommendation of the American Heart Association and American Stroke Association, randomized trial published in NEJM; acquired by Johnson & Johnson.

Having founded multiple companies, Jay fully appreciates founder’s viewpoints and needs. Jay has a broad and deep understanding of the life sciences and the complexities surrounding regulatory and reimbursement pathways. Jay has received FDA approval of multiple novel PMA, HDE, and 510k (including the first ever De Novo 510k) products and leverages this expertise through Mammoth to help founders connect their ultimate commercialization strategy to efficient FDA and CMS pathways. Jay has negotiated multiple license and merger agreements and has direct access to the leadership of many large healthcare companies. Jay has authored over 300 peer-reviewed publications, 2 books, and over 40 patents. His scientific and entrepreneurial work has been widely recognized. He serves on a number of non-profit boards including Georgia Bio (Chairman), the Global Center for Medical Innovation, TiE, American Heart Association, Southeast Medical Device Association, Beacon College, the Westminster Schools and the Advisory Board on Entrepreneurship for the Yale School of Management.